Furosemide HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 559340

CAS#: 42461-27-8 (HCl)

Description: Furosemide is a loop diuretic that inhibits the Na+/2Cl-/K+ (NKCC) symporter. It also acts as a non-competitive antagonist at GABAA receptors with ~ 100-fold greater selectivity for α6-containing receptors than α1-containing receptors.

Chemical Structure

img
Furosemide HCl
CAS# 42461-27-8 (HCl)
Instruction

Theoretical Analysis

MedKoo Cat#: 559340
Name: Furosemide HCl
CAS#: 42461-27-8 (HCl)
Chemical Formula: C12H12Cl2N2O5S
Exact Mass: 330.01
Molecular Weight: 367.197
Elemental Analysis: C, 39.25; H, 3.29; Cl, 19.31; N, 7.63; O, 21.79; S, 8.73

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 42461-27-8 (HCl). 54-31-9 (free)   41733-55-5 (sodium)    

Synonym: Furosemide; Aisemide; Aldalix; Aldic; Aluzine; Furocot; Furodiurol; Furodrix; Furomen; Furomex; Nicorol; Novosemide; NSC 269420; NSC-269420; NSC269420

IUPAC/Chemical Name: Anthranilic acid, 4-chloro-N-furfuryl-5-sulfamoyl-, hydrochloride

InChi Key: NXDBFIUCDBZBPP-UHFFFAOYSA-N

InChi Code: InChI=1S/C12H11ClN2O5S.ClH/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19;/h1-5,15H,6H2,(H,16,17)(H2,14,18,19);1H

SMILES Code: O=C(O)C1=CC(S(=O)(N)=O)=C(Cl)C=C1NCC2=CC=CO2.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 367.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Das PK, Maurya SK, Nath SS, Kumar T, Rao N, Shrivastava N. Furosemide Stress Test and Renal Resistive Index for Prediction of Severity of Acute Kidney Injury in Sepsis. Cureus. 2023 Aug 30;15(8):e44408. doi: 10.7759/cureus.44408. PMID: 37791174; PMCID: PMC10543092.


2: Janssen KM, Cho JY, Stone K, Kirsch AJ, Linam LE. Decreased percent change in renal pelvis diameter on diuretic functional magnetic resonance urography following administration of furosemide may help characterize unilateral uretero- pelvic junction obstruction. J Pediatr Urol. 2023 Aug 22:S1477-5131(23)00329-7. doi: 10.1016/j.jpurol.2023.08.014. Epub ahead of print. PMID: 37704530.


3: Mazzoldi C, Aspidi F, Romito G. Dermatologic adverse effect of subcutaneous furosemide administration in a cat. Open Vet J. 2023 Aug;13(8):1027-1031. doi: 10.5455/OVJ.2023.v13.i8.9. Epub 2023 Aug 31. PMID: 37701668; PMCID: PMC10495090.


4: Wichmann S, Lange T, Perner A, Gluud C, Itenov TS, Berthelsen RE, Nebrich L, Wiis J, Brøchner AC, Nielsen LG, Behzadi MT, Damgaard K, Andreasen AS, Strand K, Järvisalo M, Strøm T, Eschen CT, Vang ML, Hildebrandt T, Andersen FH, Sigurdsson MI, Thomar KM, Thygesen SK, Troelsen TT, Uusalo P, Jalkanen V, Illum D, Sølling C, Keus F, Pfortmueller CA, Wahlin RR, Ostermann M, Aneman A, Bestle MH. Furosemide versus placebo for fluid overload in intensive care patients-The randomised GODIF trial second version: Statistical analysis plan. Acta Anaesthesiol Scand. 2023 Sep 11. doi: 10.1111/aas.14320. Epub ahead of print. PMID: 37691474.


5: Singh S, Goel S, Duhan S, Chaudhary R, Garg A, Tantry US, Gurbel PA. Effect of Furosemide Versus Torsemide on Hospitalizations and Mortality in Patients With Heart Failure: A Meta-Analysis of Randomized Controlled Trials. Am J Cardiol. 2023 Sep 5;206:42-48. doi: 10.1016/j.amjcard.2023.08.079. Epub ahead of print. PMID: 37677884.


6: Guan C, Li C, Xu L, Che L, Wang Y, Yang C, Zhang N, Liu Z, Zhao L, Zhou B, Man X, Luan H, Xu Y. Hospitalized patients received furosemide undergoing acute kidney injury: the risk and prediction tool. Eur J Med Res. 2023 Sep 2;28(1):312. doi: 10.1186/s40001-023-01306-0. PMID: 37660080; PMCID: PMC10474726.


7: Koronaiou LA, Nannou C, Evgenidou E, Panagopoulos Abrahamsson D, Lambropoulou DA. Photo-assisted transformation of furosemide: Exploring transformation pathways, structure database and suspect and non-target workflows for comprehensive screening of unknown transformation products in wastewaters and landfill leachates. Sci Total Environ. 2023 Aug 26;904:166599. doi: 10.1016/j.scitotenv.2023.166599. Epub ahead of print. PMID: 37640083.


8: Benzi JRL, Rocha A, Colombari JC, Pego AMG, Dos Santos Melli PP, Duarte G, Lanchote VL. Determination of furosemide and its glucuronide metabolite in plasma, plasma ultrafiltrate and urine by HPLC-MS/MS with application to secretion and metabolite formation clearances in non-pregnant and pregnant women. J Pharm Biomed Anal. 2023 Oct 25;235:115635. doi: 10.1016/j.jpba.2023.115635. Epub 2023 Aug 11. PMID: 37634358.


9: Ahmad Cheema H, Azeem S, Ejaz A, Khan F, Muhammad A, Shahid A, Nashwan AJ, Maqsood MH, Dani SS, Mentz RJ, Fudim M, Fonarow GC. Efficacy and safety of torsemide versus furosemide in heart failure patients: A systematic review of randomized controlled trials. Clin Cardiol. 2023 Aug 22. doi: 10.1002/clc.24088. Epub ahead of print. PMID: 37608566.


10: Iwamoto Y, Kimura T, Ohnishi M, Kusano T, Takenouchi H, Iwamoto H, Sanada J, Fushimi Y, Katakura Y, Tatsumi F, Shimoda M, Nakanishi S, Kaku K, Mune T, Kaneto H. Simple standing test without furosemide is useful in the diagnosis of primary aldosteronism. Sci Rep. 2023 Aug 17;13(1):13381. doi: 10.1038/s41598-023-40574-y. PMID: 37591913; PMCID: PMC10435472.


11: Raina R, Sethi SK, Agrawal G, Wazir S, Bajaj N, Gupta NP, Tibrewal A, Vadhera A, Mirgunde S, Balachandran B, Sahoo J, Afzal K, Shrivastava A, Bagla J, Krishnegowda S, Konapur A, Soni K, Alhasan K, McCulloch M, Bunchman T. Use of furosemide in preterm neonates with acute kidney injury is associated with increased mortality: results from the TINKER registry. Pediatr Nephrol. 2023 Aug 15. doi: 10.1007/s00467-023-06086-7. Epub ahead of print. PMID: 37581700.


12: Hughes A. Letter to the Editor: Using Randomized Controlled Trials to Evaluate the Effectiveness of Subcutaneous Furosemide in Advanced Heart Failure Patients With Palliative Care Needs. J Palliat Med. 2023 Aug;26(8):1035-1036. doi: 10.1089/jpm.2023.0310. PMID: 37579228.


13: Kamio T, Ikegami M, Machida Y, Uemura T, Chino N, Iwagami M. Machine learning-based prognostic modeling of patients with acute heart failure receiving furosemide in intensive care units. Digit Health. 2023 Aug 11;9:20552076231194933. doi: 10.1177/20552076231194933. PMID: 37576718; PMCID: PMC10422900.


14: Li ZK, Zheng P. Acute pancreatitis caused by tigecycline and furosemide combination treatment and hypofibrinogenemia caused by tigecycline: A case report. Int J Clin Pharmacol Ther. 2023 Oct;61(10):466-470. doi: 10.5414/CP204337. PMID: 37548456.


15: Yilmaz B. Release of nifedipine, furosemide, and niclosamide drugs from the biocompatible poly(HEMA) hydrogel structures. Turk J Chem. 2022 Sep 1;46(5):1710-1722. doi: 10.55730/1300-0527.3474. PMID: 37529747; PMCID: PMC10390117.


16: Li C, Ren Q, Li X, Han H, Xie K, Wang G. Association between furosemide administration and clinical outcomes in patients with sepsis-associated acute kidney injury receiving renal replacement therapy: a retrospective observational cohort study based on MIMIC-IV database. BMJ Open. 2023 Jul 30;13(7):e074046. doi: 10.1136/bmjopen-2023-074046. PMID: 37518073; PMCID: PMC10387626.


17: Su Y, Zhang YJ, Tu GW, Hou JY, Ma GG, Hao GW, Xu RH, Luo Z. Furosemide Responsiveness Predicts Acute Kidney Injury Progression After Cardiac Surgery. Ann Thorac Surg. 2023 Jul 23:S0003-4975(23)00728-2. doi: 10.1016/j.athoracsur.2023.07.011. Epub ahead of print. PMID: 37488003.


18: To A, Davila C, Stroope S, Walton R. Case report: Resolution of oligo-anuric acute kidney injury with furosemide administration in a cat following lily toxicity. Front Vet Sci. 2023 Jul 5;10:1195743. doi: 10.3389/fvets.2023.1195743. PMID: 37476822; PMCID: PMC10354244.


19: Siddiqi AK, Javaid H, Ahmed M, Dhawadi S, Batool L, Zahid M, Muslim MO, Naeem K, Mahmood F, Hussain A. Clinical Outcomes With Furosemide Versus Torsemide in Patients With Heart Failure: An Updated Systematic Review and Meta- Analysis. Curr Probl Cardiol. 2023 Jul 13;48(11):101927. doi: 10.1016/j.cpcardiol.2023.101927. Epub ahead of print. PMID: 37453532.


20: Kulkarni NS. No Benefit With Torsemide Over Furosemide for Posthospitalization Treatment of Heart Failure. Am Fam Physician. 2023 Jul;108(1):Online. PMID: 37440752.